Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Physicians Group Services PA

Neither a doctor nor a teaching hospital

Research payments

$590,021

90 payments

Through program year 2025, Physicians Group Services PA is reported as receiving $590,021 in research payments, across 90 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $37,648 13
2024 Research $262,456 31
2023 Research $150,859 25
2022 Research $124,374 16
2019 Research $14,684 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $430,822 57 payments
  2. Pfizer Inc. $98,289 21 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $46,227 7 payments
  4. Allergan Inc. $14,684 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $377,787 43 payments
  2. Phase 3 Multicenter Openlabel Study to Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $94,005 19 payments
  3. Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine $33,488 6 payments
  4. Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age $29,389 3 payments
  5. Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $17,237 5 payments
  6. A Double Blind, Placebo- and Active Controlled Evaluation of the Safety and Efficacy of Levomilnacipran Er in Adolescent Patients With Major Depressive Disorder $14,684 5 payments
  7. M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $8,206 2 payments
  8. M21-471 Ph2b PoC Study (2068-201-008) $6,495 2 payments
  9. Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age $3,884 1 payment
  10. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $3,047 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record